glp 1 drugs news Medicare will now help pay for some GLP-1 drugs. Here's what to know The GLP-1 revolution: What UAB

Additionally, research into novel delivery technologies, such as microneedle patches and implantable devices, holds the potential to further enhance patient convenience and compliance, thereby expanding the market reach and attractiveness of GLP-1 receptor agonists

In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg

Mol Metab 18, 314 (2018)

Figure 1 In non-alcoholic fatty liver disease (NAFLD) mice ( Effects of Glucagon Like Peptide-1 Receptor Agonists on the Neurological System Autoradiography of human tissue sections with 125 I-labelled GLP-1 (7-36 amide) revealed a high content of GLP-1R in the central nervous system suggesting its potentially important role in the nervous system ( Effects on Alzheimers Disease Alzheimers disease (AD) is a progressive and irreversible neurodegenerative disease, with unclear aetiology and pathogenesis

Combination Therapies : The integration of GLP-1 agonists with other weight loss agents is under exploration, aiming to create synergies that offer superior weight loss outcomes